Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD371-CAR T cells
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD371-CAR T cells (specifically the CD371-SAVVYz-IL18 construct) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy targets CD371 (also known as CLL-1 or CLEC12A), a surface antigen highly expressed on AML blasts and leukemic stem cells but absent on healthy hematopoietic stem cells. The construct features a fully human scFv and a mutated CD28 costimulatory domain, termed 'SAVVY', which is engineered to minimize T-cell exhaustion and improve persistence. Additionally, the cells are modified to constitutively secrete interleukin-18 (IL-18), a potent immunomodulatory cytokine that enhances CAR T-cell cytotoxicity and stimulates host immune responses within the tumor microenvironment. It is currently being evaluated in Phase 1 clinical trials.
- Other names
- CLL-1 CAR-TCLL1 CAR-TCLL 1 CAR-TCLEC12A CAR-TCLEC-12A CAR-TCLEC 12A CAR-T
02
Targets
CLEC12A
Beyond the preview
Go deeper on CD371-CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD371-CAR T cells.